Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Open-label, single-dose multi-center, randomized study of FX-322 in mild to severe sensorineural hearing loss

Next Previous
X
Search
Trial Profile

Phase 1b Open-label, single-dose multi-center, randomized study of FX-322 in mild to severe sensorineural hearing loss

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FX 322 (Primary)
  • Indications Sensorineural hearing loss
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 22 Sep 2021 According to a Frequency Therapeutics Media Release, an overview of the study will be shared in a late-breaking scientific presentation at the American Academy of Otolaryngology- Head and Neck Surgery Annual Meeting and OTO experience.
    • 22 Sep 2021 Results published in the Frequency Therapeutics Media Release.
    • 22 Sep 2021 According to a Frequency Therapeutics Media Release, four additional sensorineural hearing loss (SNHL) subjects from the study achieved statistically significant hearing improvements when evaluated 8 to 12 months following initial dosing. Including the five initial responders, there are now a total of nine subjects that participated in the study have shown to have statistically significant improvements in word recognition scores.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top